NCT04798339: Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA
- State
- Under way
- Phase
- Phase 1 and Phase 2
- People
- 13 taking part
- Started
- 30 Mar 2021
- Primary completion
- 26 May 2025
- Arms
- Phase 1b: Dose Level 1, Phase 1b: Dose Level 2, Phase 2: Treatment at Maximum Tolerated Dose
- Results
- None posted
- 15 Mar 2021: Trial registered
- 30 Mar 2021: Trial started